Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Connect Biopharma Holdings Ltd CNTB

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of T cell-driven inflammatory diseases. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Ra) in development for the treatment of atopic dermatitis and asthma. Its second advanced... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:CNTB)

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire 8 days ago

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire March 19, 2024

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

GlobeNewswire February 12, 2024

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

GlobeNewswire December 12, 2023

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

GlobeNewswire December 11, 2023

Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management

Newsfile November 30, 2023

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

GlobeNewswire November 21, 2023

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

GlobeNewswire November 21, 2023

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

GlobeNewswire November 20, 2023

Opinion & Analysis (NDAQ:CNTB)

No current opinion is available.

Bullboard Posts (NDAQ:CNTB)